Stock AnalizBeam Therapeutics Inc. BEAM
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Beam Therapeutics Inc. (BEAM) is a healthcare company listed in the US with a market value of about $2.4B. In the twelve months to September 30, 2026 it had revenue of $147M and net income of -$108M, a net margin of -73.9%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 466% a year, a 5-year average ROIC of -29%.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $147M | $140M | $64M | $378M | $61M | $52M | $24000 | $18000 |
| Net income | -$108M | -$80M | -$377M | -$133M | -$289M | -$371M | -$195M | -$78M |
| Free cash flow | -$398M | -$360M | -$356M | -$183M | -$26M | -$113M | -$112M | -$85M |
| EPS (diluted) | $-0.87 | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-4.19 | $-14.05 |
| Net margin | -73.9% | -57.2% | -593.1% | -35.1% | -474.5% | -714.9% | -810800.0% | -435100.0% |
| ROIC | — | -27.6% | -36.7% | -12.1% | -29.3% | -40.5% | -38.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $49.85, 118% above the current price; targets range from $26.00 to $80.00; the consensus rating is “Strong buy”; expected EPS is $-4.53 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Beam Therapeutics pay a dividend?
Not currently.
Is Beam Therapeutics a good stock to buy?
We do not give buy or sell advice. Beam Therapeutics scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.